The following codes as of January 2020 are provided as a reference and may be relevant when billing for KEYTRUDA and its administration. Consult the relevant manual and/or other guidelines for a description of each code to determine the appropriateness of its use and for information on additional codes. Diagnosis codes should be selected only by a health care professional. You are solely responsible for determining the appropriate codes and for any action you take in billing.

When submitting a claim for KEYTRUDA, always verify coding requirements with the relevant payer. Coding requirements may vary by insurer or plan; please refer to the payer-specific policies to understand what may be covered.

Check with the relevant payer regarding guidance on which diagnoses they will recognize and the applicability of secondary codes. Health care professionals are solely responsible for selecting codes that appropriately reflect the patient’s diagnosis, the services rendered, and the applicable payers’ guidelines.

Providers should document the diagnosis with a sufficiently high degree of specificity based on the information available to enable the identification of the most appropriate code. Although CMS has said that an unspecified code may be appropriate in some cases, CMS has advised that you should always code with as much specificity as possible consistent with the clinical documentation.

Merck and its agents make no warranties concerning the accuracy or appropriateness of this information for your particular use given the frequent changes in public and private payer billing. Merck cautions that payer-coding requirements vary and can frequently change, so it is important to regularly check with each payer or, where applicable, the Medicare Administrative Contractor as to payer-specific requirements. The use of this information does not guarantee payment or that any payment received will cover your costs.

For information about billing and coding products other than KEYTRUDA, please contact the manufacturer of the product or the applicable payer.


KEYTRUDA, in combination with LENVIMA® (lenvatinib), is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.

FDA-Approved Dosing

The FDA-approved dose of KEYTRUDA is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks in combination with LENVIMA 20 mg orally once daily until disease progression, unacceptable toxicity, or for KEYTRUDA, up to 24 months in patients without disease progression.

  • The recommended dosage of LENVIMA for patients with endometrial carcinoma and severe renal impairment (creatinine clearance <30 mL/min) is 10 mg orally once daily. LENVIMA has not been studied in patients with end stage renal disease.
  • The recommended dosage of LENVIMA for patients with endometrial carcinoma and severe hepatic impairment (Child-Pugh C) is 10 mg orally once daily.
  • LENVIMA is taken once daily, with or without food, at the same time each day. If a dose is missed and cannot be taken within 12 hours, skip that dose and take the next dose at the usual time.
  • When administering KEYTRUDA and LENVIMA in combination, interrupt one or both drugs or dose reduce LENVIMA as appropriate.

Possible relevant diagnosis codes for advanced endometrial carcinoma

Learn more about each diagnosis code and descriptor by selecting from the series options below.


C54: Malignant Neoplasm of Corpus Uteri4

    C54.0 Malignant neoplasm of isthmus uteri
    C54.1 Malignant neoplasm of endometrium
    C54.3 Malignant neoplasm of fundus uteri
    C54.8 Malignant neoplasm of overlapping sites of corpus uteri
    C54.9 Malignant neoplasm of corpus uteri, unspecified

C55: Malignant Neoplasm of Uterus, Part Unspecified4

C55 Malignant neoplasm of uterus, part unspecified

C57: Malignant Neoplasm of Other and unspecified Female Genital Organs4

C57.8 Malignant neoplasm of overlapping sites of female genital organs